<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7017049/results/search/disease/results.xml">
  <result pre="receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated" exact="thrombocytopenia" post="refractory to immunomodulatory and antiviral drugs. These effects were"/>
  <result pre="Therapeutic eltrombopag concentrations inhibited HCMV replication in human fibroblasts and" exact="adult" post="mesenchymal stem cells infected with six different virus strains"/>
  <result pre="agonist that is used for the treatment of thrombocytopenia, including" exact="hepatitis" post="C virus-associated thrombocytopenia [1,2,3]. Its use has also been"/>
  <result pre="used for the treatment of thrombocytopenia, including hepatitis C virus-associated" exact="thrombocytopenia" post="[1,2,3]. Its use has also been suggested for the"/>
  <result pre="safety and efficacy [4,5,6,7,8,9]. Human cytomegalovirus (HCMV) reactivation and HCMV-associated" exact="disease" post="are leading reasons for the failure of hematopoietic stem"/>
  <result pre="cytomegalovirus disease, is associated with severe hematological side effects, including" exact="thrombocytopenia" post="[14,15,16]. A case report described the use of eltrombopag"/>
  <result pre="in an immunocompetent patient who suffered from human cytomegalovirus (HCMV)-associated" exact="thrombocytopenia" post="[17]. Immunosuppressive treatment for thrombocytopenia (prednisone, intravenous immunoglobulin, dapsone),"/>
  <result pre="suffered from human cytomegalovirus (HCMV)-associated thrombocytopenia [17]. Immunosuppressive treatment for" exact="thrombocytopenia" post="(prednisone, intravenous immunoglobulin, dapsone), in combination with antiviral therapy"/>
  <result pre="outcome in the case report of the patient with HCMV-associated" exact="thrombocytopenia" post="[17]. Indeed, we found that eltrombopag exerts anti-HCMV effects"/>
  <result pre="Chemical (via Biomol GmbH, Hamburg, Germany). 2.2. Cells and Viruses" exact="Primary" post="human foreskin fibroblasts (HFFs) and adipose-derived adult mesenchymal stem"/>
  <result pre="Cells and Viruses Primary human foreskin fibroblasts (HFFs) and adipose-derived" exact="adult" post="mesenchymal stem cells (ASCs) were cultivated as previously described"/>
  <result pre="[20]. HCMV strains Davis and Towne were received from the" exact="American" post="Type Culture Collection (ATCC) (Manassas, VA, USA). Virus stocks"/>
  <result pre="ASCs were incubated with HCMV at the indicated multiplicities of" exact="infection" post="(MOIs). After incubation for 1-h, cells were washed with"/>
  <result pre="[18,23], cells producing HCMV-specific antigens were detected 24 h post" exact="infection" post="by immunoperoxidase staining, using monoclonal antibodies directed against the"/>
  <result pre="IEA, MAB8131, Millipore, Temecula, CA, USA), and 120 h post" exact="infection" post="by immunoperoxidase staining, using monoclonal antibodies directed against UL55-encoded"/>
  <result pre="UK). Effects of eltrombopag on murine cytomegalovirus were determined by" exact="visual" post="scoring of cytopathogenic effect (CPE) formation (detected 120 h"/>
  <result pre="were combined at equimolar concentrations or used as single agents." exact="Combined" post="effects were determined by staining for HCMV LA. Combination"/>
  <result pre="the manufacturer’s instructions. 2.6. Virus Yield Assay The amount of" exact="infectious" post="virus was determined by virus yield assay in a"/>
  <result pre="[23]. Virus titres were expressed as 50% of tissue culture" exact="infectious" post="dose (TCID50/mL), 120 h post infection. 2.7. Immunoblotting Immunoblotting"/>
  <result pre="characterized by the expression of immediate early, early, and late" exact="viral" post="genes. Immediate early genes are transcribed immediately after infection"/>
  <result pre="late viral genes. Immediate early genes are transcribed immediately after" exact="infection" post="and do not depend on synthesis of viral DNA"/>
  <result pre="immediately after infection and do not depend on synthesis of" exact="viral" post="DNA or transcription of proteins. Delayed early proteins are"/>
  <result pre="depend on synthesis of viral DNA or transcription of proteins." exact="Delayed" post="early proteins are represented by the viral DNA polymerase,"/>
  <result pre="transcription of proteins. Delayed early proteins are represented by the" exact="viral" post="DNA polymerase, and other viral functions required for viral"/>
  <result pre="proteins are represented by the viral DNA polymerase, and other" exact="viral" post="functions required for viral DNA synthesis, and some viral"/>
  <result pre="the viral DNA polymerase, and other viral functions required for" exact="viral" post="DNA synthesis, and some viral structural proteins. Late genes"/>
  <result pre="other viral functions required for viral DNA synthesis, and some" exact="viral" post="structural proteins. Late genes encode mostly structural proteins used"/>
  <result pre="structural proteins. Late genes encode mostly structural proteins used in" exact="viral" post="assembly and packaging, and are generally expressed subsequent to"/>
  <result pre="early genes [27]. To better define which phases of the" exact="viral" post="replication cycle are affected by eltrombopag, the drug was"/>
  <result pre="its anti-HCMV effects. Drug addition 1-h or 24 h post" exact="infection" post="was sufficient to achieve maximum inhibition of HCMV LA"/>
  <result pre="cycle characterized by LA expression. Drug addition 48 h post" exact="infection" post="resulted in reduced effects compared to drug addition 1-h"/>
  <result pre="effects compared to drug addition 1-h or 24 h post" exact="infection" post="(Figure 2B, Table S1). 3.2. Eltrombopag Inhibits HCMV Expression"/>
  <result pre="case report on an immunocompetent patient, who suffered from HCMV-associated" exact="thrombocytopenia" post="and recovered after eltrombopag therapy [17]. This response had"/>
  <result pre="been shown to inhibit the replication of severe fever with" exact="thrombocytopenia" post="syndrome virus, a member of the genus Banyangvirus (Phenuiviridae)"/>
  <result pre="shown to inhibit the replication of severe fever with thrombocytopenia" exact="syndrome" post="virus, a member of the genus Banyangvirus (Phenuiviridae) [49]."/>
  <result pre="the anti-HCMV effects of eltrombopag are primarily of relevance for" exact="anemia" post="patients at risk of HCMV disease, for whom eltrombopag"/>
  <result pre="cytopenias after haematopoietic stem cell transplantation, as HCMV reactivation and" exact="disease" post="is a major reason for transplantation failure. Supplementary Materials"/>
  <result pre="of eltrombopag on HCMV immediate early antigen (IEA) expression in" exact="primary" post="human foreskin fibroblasts (HFFs), Table S1: Effects of eltrombopag"/>
  <result pre="The authors declare no conflicts of interest. References References 1.GillH.WongR.S.M.KwongY.L.From" exact="chronic" post="immune thrombocytopenia to severe aplastic anemia: Recent insights into"/>
  <result pre="declare no conflicts of interest. References References 1.GillH.WongR.S.M.KwongY.L.From chronic immune" exact="thrombocytopenia" post="to severe aplastic anemia: Recent insights into the evolution"/>
  <result pre="Allogeneic Hematopoietic Stem Cell TransplantationCase Rep. Oncol.20181119119510.1159/00048722929681820 5.TangC.ChenF.KongD.MaQ.DaiH.YinJ.LiZ.ChenJ.ZhuX.MaoX.WuD.TangX.Successful treatment of" exact="secondary" post="poor graft function post allogeneic hematopoietic stem cell transplantation"/>
  <result pre="Oncol.20181110310.1186/s13045-018-0649-630115080 6.FuH.ZhangX.HanT.MoX.WangY.ChenH.HanW.WangJ.WangF.YanC.ZhangY.SunY.LiuK.HuangX.XuL.Eltrombopag is an effective and safe therapy for refractory" exact="thrombocytopenia" post="after haploidentical hematopoietic stem cell transplantationBone Marrow. Transplant.2019541310131810.1038/s41409-019-0435-230664724 7.GuentherK.L.CherukuP.S.CashA.SmithR.H.AlvaradoL.J.BurkettS.TownsleyD.M.WinklerT.LarochelleA.Eltrombopag"/>
  <result pre="graft functionBone Marrow. Transplant.2019541346135310.1038/s41409-019-0442-330679824 9.RiveraD.BastidaJ.M.Lopez-CorralL.Sanchez-GuijoF.CabreroM.MartinA.PerezE.Lopez-ParraM.AvendañoA.VeigaA.et al.Usefulness of eltrombopag for treating" exact="thrombocytopenia" post="after allogeneic stem cell transplantationBone Marrow. Transplant.20195475776110.1038/s41409-018-0368-130356164 10.ChoS.Y.LeeD.G.KimH.J.Cytomegalovirus Infections"/>
  <result pre="treating thrombocytopenia after allogeneic stem cell transplantationBone Marrow. Transplant.20195475776110.1038/s41409-018-0368-130356164 10.ChoS.Y.LeeD.G.KimH.J.Cytomegalovirus" exact="Infections" post="after Hematopoietic Stem Cell Transplantation: Current Status and Future"/>
  <result pre="Mol. Sci.201920266610.3390/ijms20112666 11.LjungmanP.de la CamaraR.RobinC.CrocchioloR.EinseleH.HillJ.A.HubacekP.NavarroD.CordonnierC.WardK.N.et al.Guidelines for the management of" exact="cytomegalovirus infection" post="in patients with haematological malignancies and after stem cell"/>
  <result pre="Sci.201920266610.3390/ijms20112666 11.LjungmanP.de la CamaraR.RobinC.CrocchioloR.EinseleH.HillJ.A.HubacekP.NavarroD.CordonnierC.WardK.N.et al.Guidelines for the management of cytomegalovirus" exact="infection" post="in patients with haematological malignancies and after stem cell"/>
  <result pre="after stem cell transplantation from the 2017 European Conference on" exact="Infections" post="in Leukaemia (ECIL 7)Lancet Infect. Dis.201919e260e27210.1016/S1473-3099(19)30107-031153807 12.PandeA.DubberkeE.R.Cytomegalovirus Infections of"/>
  <result pre="Conference on Infections in Leukaemia (ECIL 7)Lancet Infect. Dis.201919e260e27210.1016/S1473-3099(19)30107-031153807 12.PandeA.DubberkeE.R.Cytomegalovirus" exact="Infections" post="of the Stem Cell Transplant Recipient and Hematologic Malignancy"/>
  <result pre="14.McGavinJ.K.GoaK.L.Ganciclovir: an update of its use in the prevention of" exact="cytomegalovirus infection" post="and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as"/>
  <result pre="an update of its use in the prevention of cytomegalovirus" exact="infection" post="and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as"/>
  <result pre="of its use in the prevention of cytomegalovirus infection and" exact="disease" post="in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as preemptive therapy"/>
  <result pre="in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as preemptive therapy for" exact="cytomegalovirus infection" post="post allogeneic stem cell transplantationTranspl. Infect. Dis.2007910210710.1111/j.1399-3062.2006.00183.x17461994 16.MatsumotoK.ShigemiA.IkawaK.KanazawaN.FujisakiY.MorikawaN.TakedaY.Risk factors"/>
  <result pre="transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral valganciclovir as preemptive therapy for cytomegalovirus" exact="infection" post="post allogeneic stem cell transplantationTranspl. Infect. Dis.2007910210710.1111/j.1399-3062.2006.00183.x17461994 16.MatsumotoK.ShigemiA.IkawaK.KanazawaN.FujisakiY.MorikawaN.TakedaY.Risk factors"/>
  <result pre="allogeneic stem cell transplantationTranspl. Infect. Dis.2007910210710.1111/j.1399-3062.2006.00183.x17461994 16.MatsumotoK.ShigemiA.IkawaK.KanazawaN.FujisakiY.MorikawaN.TakedaY.Risk factors for ganciclovir-induced" exact="thrombocytopenia" post="and leukopeniaBiol. Pharm. Bull.20153823523810.1248/bpb.b14-0058825747982 17.SimpsonJ.D.MatthewsG.V.BrightonT.A.JosephJ.E.Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin"/>
  <result pre="16.MatsumotoK.ShigemiA.IkawaK.KanazawaN.FujisakiY.MorikawaN.TakedaY.Risk factors for ganciclovir-induced thrombocytopenia and leukopeniaBiol. Pharm. Bull.20153823523810.1248/bpb.b14-0058825747982 17.SimpsonJ.D.MatthewsG.V.BrightonT.A.JosephJ.E.Cytomegalovirus-associated" exact="thrombocytopenia" post="treated with thrombopoietin receptor agonistIntern. Med. J.2016461096109910.1111/imj.1318127633469 18.CinatlJ.CinatlJ.WeberB.RabenauH.GümbelH.O.ChenotJ.F.ScholzM.EnckeA.DoerrH.W.In vitro"/>
  <result pre="19.BaerP.C.BrzoskaM.GeigerH.Epithelial differentiation of human adipose-derived stem cellsMethods Mol. Biol.201170228929821082410 20.CinatlJ.Jr.KotchetkovR.ScholzM.CinatlJ.VogelJ.U.DrieverP.H.DoerrH.W.Human" exact="cytomegalovirus infection" post="decreases expression of thrombospondin-1 independent of the tumor suppressor"/>
  <result pre="differentiation of human adipose-derived stem cellsMethods Mol. Biol.201170228929821082410 20.CinatlJ.Jr.KotchetkovR.ScholzM.CinatlJ.VogelJ.U.DrieverP.H.DoerrH.W.Human cytomegalovirus" exact="infection" post="decreases expression of thrombospondin-1 independent of the tumor suppressor"/>
  <result pre="20.CinatlJ.Jr.KotchetkovR.ScholzM.CinatlJ.VogelJ.U.DrieverP.H.DoerrH.W.Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the" exact="tumor" post="suppressor protein p53Am. J. Pathol.199915528529210.1016/S0002-9440(10)65122-X10393860 21.VogelJ.U.OtteJ.KochF.GümbelH.DoerrH.W.CinatlJ.Jr.Role of human cytomegalovirus"/>
  <result pre="significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and" exact="hepatitis" post="C virus protease inhibitors boceprevir and telaprevirAntimicrob. Agents Chemother.2014586704670910.1128/AAC.03091-1425155600"/>
  <result pre="nonpeptide thrombopoietin receptor agonistStem. Cells20092742443010.1634/stemcells.2008-036619038790 30.RothM.WillB.SimkinG.NarayanagariS.BarreyroL.BartholdyB.TamariR.MitsiadesC.S.VermaA.SteidlEltrombopag inhibits the proliferation of" exact="leukemia" post="cells via reduction of intracellular iron and induction of"/>
  <result pre="linked to protein-based drug carrier systemsBiochem. Biophys. Res. Commun.20043231236124010.1016/j.bbrc.2004.08.22315451429 39.ZwezdarykK.J.FerrisM.B.StrongA.L.MorrisC.A.BunnellB.A.DhurandharN.V.GimbleJ.M.SullivanD.E.Human" exact="cytomegalovirus infection" post="of human adipose-derived stromal/stem cells restricts differentiation along the"/>
  <result pre="to protein-based drug carrier systemsBiochem. Biophys. Res. Commun.20043231236124010.1016/j.bbrc.2004.08.22315451429 39.ZwezdarykK.J.FerrisM.B.StrongA.L.MorrisC.A.BunnellB.A.DhurandharN.V.GimbleJ.M.SullivanD.E.Human cytomegalovirus" exact="infection" post="of human adipose-derived stromal/stem cells restricts differentiation along the"/>
  <result pre="resistance of human cytomegalovirusClin. Microbiol. Rev.20102368971210.1128/CMR.00009-1020930070 47.ChouS.ErcolaniR.J.VanarsdallA.L.Differentiated Levels of Ganciclovir" exact="Resistance" post="Conferred by Mutations at Codons 591 to 603 of"/>
  <result pre="Library with a Two-Tier System Identifies an Entry Inhibitor of" exact="Severe" post="Fever with Thrombocytopenia Syndrome VirusViruses20191138510.3390/v11040385 50.SunY.BaoQ.XuanB.XuW.PanD.LiQ.QianZ.Human Cytomegalovirus Protein pUL38"/>
  <result pre="with a Two-Tier System Identifies an Entry Inhibitor of Severe" exact="Fever" post="with Thrombocytopenia Syndrome VirusViruses20191138510.3390/v11040385 50.SunY.BaoQ.XuanB.XuW.PanD.LiQ.QianZ.Human Cytomegalovirus Protein pUL38 Prevents"/>
  <result pre="Two-Tier System Identifies an Entry Inhibitor of Severe Fever with" exact="Thrombocytopenia" post="Syndrome VirusViruses20191138510.3390/v11040385 50.SunY.BaoQ.XuanB.XuW.PanD.LiQ.QianZ.Human Cytomegalovirus Protein pUL38 Prevents Premature Cell"/>
  <result pre="System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia" exact="Syndrome" post="VirusViruses20191138510.3390/v11040385 50.SunY.BaoQ.XuanB.XuW.PanD.LiQ.QianZ.Human Cytomegalovirus Protein pUL38 Prevents Premature Cell Death"/>
  <result pre="Inhibitor of Severe Fever with Thrombocytopenia Syndrome VirusViruses20191138510.3390/v11040385 50.SunY.BaoQ.XuanB.XuW.PanD.LiQ.QianZ.Human Cytomegalovirus" exact="Protein" post="pUL38 Prevents Premature Cell Death by Binding to Ubiquitin-Specific"/>
  <result pre="Fever with Thrombocytopenia Syndrome VirusViruses20191138510.3390/v11040385 50.SunY.BaoQ.XuanB.XuW.PanD.LiQ.QianZ.Human Cytomegalovirus Protein pUL38 Prevents" exact="Premature" post="Cell Death by Binding to Ubiquitin-Specific Protease 24 and"/>
  <result pre="eltrombopag on human cytomegalovirus (HCMV) late antigen (LA) expression in" exact="primary" post="human foreskin fibroblasts (HFFs). (A) Representative dose–response curves showing"/>
  <result pre="also provided. Eltrombopag was continuously present from the time of" exact="virus infection." post="(B) Representative photographs and Western blots demonstrating the effects"/>
  <result pre="(A,B), HFFs were infected with HCMV strain Hi91 (multiplicity of" exact="infection" post="(MOI) 0.02). HCMV LA expression was detected 120 h"/>
  <result pre="eltrombopag on HCMV replication and at different stages of the" exact="viral" post="replication cycle. HFFs were infected with HCMV strain Hi91"/>
  <result pre="treatment during the 1-h adsorption period, after drug addition post" exact="infection" post="following the 1-h virus adsorption period, after drug addition"/>
  <result pre="infection. * p &amp;lt; 0.05 Figure 3 Eltrombopag inhibits HCMV" exact="infection" post="by iron depletion. (A) Representative dose–response curve indicating the"/>
  <result pre="HFFs were infected at an MOI of 0.02 and adipose-derived" exact="adult" post="mesenchymal stem cells (ASCs) at an MOI of 5."/>
  <result pre="50% (IC50) are provided. IC50 (µM) IC50 (µM) Virus Strain/Isolate" exact="Resistance" post="Mutations Ganciclovir Cidofovir Hi91 n/a 0.71 ± 0.57 0.31"/>
 </snippets>
</snippetsTree>
